AVAILABLE IN THE US

JYLAMVO®

(methotrexate) Oral Solution

The only approved methotrexate oral solution for adults. No pill splitting, pill crushing, compounding, or injections required.1,2

Actor portrayal

INDICATIONS

JYLAMVO is indicated for adults with1:

  • Acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen
  • Mycosis fungoides (cutaneous T-cell lymphoma) as a single agent or as part of a combination chemotherapy regimen
  • Relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination chemotherapy regimen
  • Rheumatoid arthritis
  • Severe psoriasis

Please click here for the full Prescribing Information, including Boxed Warning.

WHY JYLAMVO

Oral solutions may provide more accurate dosing than splitting pills or compounding.3,4 JYLAMVO, an oral methotrexate solution, offers an alternate treatment regimen for you and your patients.1

Icon for no pill breaking

No crushing
or splitting

Icon for no compounding

No
compounding

Icon for no injections

No
injections

Image of Jylamvo box
Orange flavor1
Sweet, palatable taste1,5*
Does not require refrigeration and lasts 90 days once opened1
*
In 2 single-dose (10 mg and 2.5 mg) bioequivalence studies of the 2 mg/mL methotrexate oral solution in 24 healthy male subjects, JYLAMVO has been shown to have a sweet, palatable taste.5
Illustration representing contacting a representative

Contact a representative

For questions about JYLAMVO or to request an appointment, please email sales@shorlaoncology.com

RECOMMENDED DOSAGE1

Acute Lymphoblastic Leukemia
  • Starting dosage of 20 mg/m2 orally once weekly, as part of a combination chemotherapy maintenance regimen
  • After initiation, periodically monitor absolute neutrophil count (ANC) and platelet count and adjust the dose to maintain ANC at a desirable level and to reduce excessive myelosuppression
Mycosis Fungoides
  • 25 to 75 mg orally once weekly when administered as a single agent
  • 10 mg/m2 orally twice weekly as part of a combination chemotherapy regimen
Relapsed or Refractory Non-Hodgkin Lymphoma
  • 2.5 mg orally 2 to 4 times per week (maximum 10 mg per week) as part of a metronomic combination chemotherapy regimen
Rheumatoid Arthritis
  • 7.5 mg orally once weekly with escalation to achieve optimal response. Administer folic acid or folinic acid to reduce the risk of methotrexate adverse reactions
Psoriasis
  • 10 to 25 mg orally once weekly until an adequate response is achieved; do not exceed a dose of 30 mg per week. Administer folic acid or folinic acid supplementation to reduce the risk of methotrexate adverse reactions
Dosages >20 mg once weekly result in an increased risk of serious adverse reactions, including myelosuppression.1

For additional information, including dosing and administration, please see the full Prescribing Information here.

Icon image of a thermometer

STORAGE

No refrigeration required1

Before opening1:

  • Store at room temperature (20° C to 25° C; 68° F to 77° F)

After opening1:

  • Store at room temperature (20° C to 25° C; 68° F to 77° F)
  • Keep the bottle tightly closed
  • After first opening, discard any unused medicine after 3 months

JYLAMVO HCP Product Fact Sheet

Dosing information, billing codes, ordering information, and more—ready to download and print.

Image of Jylamvo product fact sheet

JYLAMVO HCP Product Fact Sheet

Dosing information, billing codes, ordering information, and more—ready to download and print.

Download
Icon for $5 copay

PATIENT ASSISTANCE

When prescribed, JYLAMVO is available for as little as $5 for commercially insured patients. No cards, coupons, or calls required.

View eligibility restrictions

HOW TO ORDER JYLAMVO

Authorized Distributors

Unit of Sale
60 mL bottle
NDC
81927-204-01
Strength
2 mg/mL
Morris Dickson
#010471
CuraScript SD
#481084

Order Direct

Shorla Oncology representatives are available to assist you from 8 AM to 5 PM CT.

Icon of telephone

CALL844-974-6752, option 2

Icon of FAX machine

FAX414-501-3169

Illustration representing requesting online information

Request medical information

Contact Shorla Oncology
Medical Information at medicalinfo @shorlaoncology.com or call 844-9-SHORLA

Illustration representing an reporting an adverse event

Report an adverse event

Please call Shorla Oncology at 844-9-SHORLA

The information contained on this page is intended for US audiences only.

All trademarks are the property of their respective owners.

References: 1.  JYLAMVO [prescribing information]. Cambridge, MA: Shorla Oncology; October 2023. 2. U.S. Food & Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed November 29, 2023. https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm 3. Abu-Geras D, Hadziomerovic D, Leau A, et al. Accuracy of tablet splitting and liquid measurements: an examination of who, what and how. J Pharm Pharmacol. 2017;69(5):603-612. doi:10.1111/jphp.12671 4. Logrippo S, Ricci G, Sestili M, et al. Oral drug therapy in elderly with dysphagia: between a rock and a hard place! Clin Interv Aging. 2017;12:241-251. doi:10.2147/CIA.S121905 5. Penton J, Winslade J, Roberts D, Conroy S. AB1101 The development of a palatable, stable oral methotrexate solution. Ann Rheum Dis. 2018;77:1659. doi:10.1136/annrheumdis-2018-eular.4596

SH-JYL-104 01/2024